SGI-1776, CAS number 1025065-69-3, is a small molecule inhibitor that targets PIM1 and PIM2, two enzymes that play essential roles in cell proliferation and survival. This molecule has gained significant attention in recent years for its potential in the treatment of various conditions, including cancer.
Top 10 Keywords:
SGI-1776 has shown promising results in the treatment of various cancers. By inhibiting PIM1 and PIM2 activity, SGI-1776 can limit tumor growth, promote apoptosis (programmed cell death), and improve overall outcomes in cancer patients.
SGI-1776 inhibits the activity of PIM1 and PIM2, two enzymes that play essential roles in cell survival and proliferation. By blocking these enzymes, SGI-1776 can promote programmed cell death and limit tumor cell growth in various types of cancers, including leukemia, lymphoma, and solid tumors.
PIM1 and PIM2 are serine/threonine kinases that play essential roles in cell proliferation, survival, and differentiation. These enzymes are frequently upregulated in various types of cancer and have been associated with an increased risk of tumor progression and resistance to chemotherapy. SGI-1776 binds to PIM1 and PIM2, inhibiting their activity, and limiting cancer cell growth and progression.
SGI-1776 is generally considered safe when used as directed. However, like all drugs, SGI-1776 has the potential to cause side effects. Common side effects may include nausea, vomiting, diarrhea, and fatigue. More severe side effects may include liver damage, heart problems, or infections. Patients taking SGI-1776 should be closely monitored for any signs of adverse reactions.
As with any drug, the use of SGI-1776 can cause side effects, which may vary from person to person. Common side effects of SGI-1776 may include nausea, vomiting, diarrhea, and fatigue. More severe side effects of SGI-1776 may include liver damage, heart problems, or infections.
The dosing information for SGI-1776 may vary depending on the condition being treated and the patient's age, weight, and overall health. SGI-1776 is usually taken orally, either with food or without food, as directed by a physician. The recommended dose of SGI-1776 may range from 100 to 500 mg.
SGI-1776 is a promising small molecule inhibitor that targets PIM1 and PIM2, offering potential benefits in the treatment of various types of cancer. The drug has shown great potential in preclinical and clinical trials, providing hope for the development of new treatments for cancer. However, further research is required to determine the long-term effectiveness and safety of SGI-1776, and patients should always consult with their physician before using any pharmaceutical products.